博瑞医药,688166,收入构成,报告日期,2021-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 权益分成收入,3614,0,3614,100%,13.36% 其他(补充),212,23,190,89.27%,0.7% 技术收入,2022,883,1140,56.35%,4.21% 产品销售收入,42064,19949,22114,52.57%,81.73% 博瑞医药,688166,收入构成,报告日期,2020-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 制剂类,3617,1102,2515,69.53%,6.89% 原料药-其他类产品,16005,9580,6426,40.15%,17.6% 原料药-免疫抑制类,7171,2834,4337,60.48%,11.88% 原料药-抗真菌类,25122,8029,17093,68.04%,46.81% 原料药-抗病毒类,15131,12131,3000,19.83%,8.22% 其他(补充),167,91,76,45.5%,0.21% 技术转让或服务,4701,1632,3069,65.28%,8.4% 产品权益分成收入,6624,-- ,-- ,--,0% 博瑞医药,688166,收入构成,报告日期,2020-06-30, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 权益分成收入,3288,0,3288,100%,18.33% 其他(补充),14,32,-18,-131.97%,-0.1% 技术收入,2853,579,2274,79.69%,12.67% 产品销售收入,24176,11776,12399,51.29%,69.11% 博瑞医药,688166,收入构成,报告日期,2019-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 其他(补充),7,4,3,42.47%,0.01% 其他类产品,9004,3660,5343,59.34%,18.77% 抗真菌类,20359,8339,12020,59.04%,42.22% 免疫抑制类,4254,1336,2918,68.6%,10.25% 产品权益分成收入,3755,-- ,-- ,--,0% 技术转让或服务,7915,851,7063,89.25%,24.81% 抗病毒类,5022,3900,1122,22.34%,3.94% 博瑞医药,688166,收入构成,报告日期,2019-03-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 权益分成收入,1473,0,1473,100%,26.14% 其他(补充),1,0,1,91.68%,0.02% 产品销售收入,5814,2810,3005,51.68%,53.34% 技术收入,1658,503,1155,69.66%,20.5% 博瑞医药,688166,收入构成,报告日期,2018-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 权益分成收入,2600,0,2600,100%,10.92% 技术收入,3203,1265,1937,60.49%,8.13% 其他(补充),107,81,26,24.49%,0.11% 产品销售收入,34841,15584,19257,55.27%,80.84% 博瑞医药,688166,收入构成,报告日期,2017-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 权益分成收入,766,0,766,100%,4.11% 其他(补充),109,84,25,22.61%,0.13% 技术收入,3561,1098,2463,69.17%,13.19% 产品销售收入,27241,11828,15413,56.58%,82.57% 博瑞医药,688166,收入构成,报告日期,2016-12-31, 按产品,收入(万元),成本(万元),利润(万元),毛利率,利润占比 权益分成收入,646,0,646,100%,5.58% 技术收入,1615,1030,585,36.21%,5.05% 产品销售收入,17821,7474,10347,58.06%,89.37% 其他(补充),11,-- ,-- ,--,0%